Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Consumption of More Ideal Food Options (COMIDA: Consumo de Opciones Más Ideales De Alimentos)

Phase 2

Conditions: Obesity
Overweight

Interventions: Behavioral: Initial in-person individual diet and exercise counseling (N vs. Y)
Behavioral: Thrice weekly diet and exercise text messages (N vs. Y)
Behavioral: Weekly telephone support (N vs. Y)
Behavioral: Self-monitoring tools (N vs. Y) (for diet and weight)

First Posted Date: 2019-02-22

Last Posted Date: 2025-06-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1785

Registration Number: NCT03851458

Locations: 🇺🇸
Mexican Consulate's Ventanilla de Salud (VDS), New York, New York, United States

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Phase 1

Completed

Conditions: Advanced BRAF Mutant Cancers

Interventions: Drug: Binimetinib
Drug: Encorafenib

First Posted Date: 2019-02-18

Last Posted Date: 2024-10-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03843775

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity), Commack, New York, United States

and more 1 locations

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

Completed

Conditions: Cutaneous Melanoma

Interventions: Behavioral: Demographics Questionnaire
Behavioral: Adjuvant Treatment Beliefs Scale10
Behavioral: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
Behavioral: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13
Behavioral: Decisional Regret14
Behavioral: Clinician Preference for Treatment

First Posted Date: 2019-02-18

Last Posted Date: 2023-01-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 38

Registration Number: NCT03843593

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Early Phase 1

Active, not recruiting

Conditions: Solid Tumors
Identified by NGS, PCR or IHC

Interventions: Drug: Pembrolizumab

First Posted Date: 2019-02-06

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03832569

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)

Interventions: Drug: Zanubrutinib
Drug: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2019-01-31

Last Posted Date: 2025-03-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 230

Registration Number: NCT03824483

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
Massachusetts General Hospital (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment

Active, not recruiting

Conditions: Fertility Preservation
Breast Cancer

Interventions: Behavioral: web-based questionnaire

First Posted Date: 2019-01-28

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 209

Registration Number: NCT03817814

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors

Early Phase 1

Active, not recruiting

Conditions: Solid Tumors
Preoperative Aerobic Training

Interventions: Behavioral: treadmill walking Dose-Finding / Escalation
Behavioral: treadmill walking (Proof-of-Concept)

First Posted Date: 2019-01-23

Last Posted Date: 2025-04-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT03813615

Locations: 🇺🇸
University of California, Los Angeles (Data Analysis only), Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 5 locations

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: Dacomitinib
Drug: Osimertinib

First Posted Date: 2019-01-22

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT03810807

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 4 locations

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2019-01-18

Last Posted Date: 2024-04-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT03810105

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 5 locations

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Phase 2

Active, not recruiting

Conditions: TNBC - Triple-Negative Breast Cancer
Triple Negative Breast Cancer
NSCLC
NSCLC Stage IV
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
NSCLC Stage IV Without EGFR/ALK Mutation

Interventions: Radiation: Sterotactic Body Radiotherapy/SBRT
Drug: Standard of care

First Posted Date: 2019-01-17

Last Posted Date: 2025-04-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 107

Registration Number: NCT03808662

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy